Table 1: Demographic and treatment characteristics of children treated with high dose (HD), moderate dose (MD), and low dose (LD) Infliximab.

No.Age (yr)GenderEthnicityOcular diagnosisSystemic diagnosisAge at diagnosis (yr)Age at starting treatment (yr)Failed meds before INFDuration of treatment with Steroids before INF (mo)

HD120FHAnteriorERA1520MTX, PRED, TPRED56
27FHAnteriorPoly JIA57MTX, PRED, TPRED22
39FHAnteriorIdiopathic79MTX, TPRED, PRED, MMF20
411FHAnteriorCNO911MTX, TPRED, PRED22
516MCIntermediateIdiopathic816MTX, PRED, TPRED80
618FHPosteriorIdiopathic1318MTX, TPRED56
76FHPanuveitisIdiopathic56MTX, TPRED10
87MCPanuveitisVKH5.57MTX, TPRED12
915FHPanuveitisVKH1015MTX, PRED, TPRED56

MD104MCAnteriorPSA34MTX/TPRED10
1113MCAnteriorERA11.513MTX/TPRED12
1213FCAnteriorOligo JIA811MTX, TPRED36
132FHAnteriorOligo JIA12MTX, TPRED10
146MCAnteriorOligo JIA3.86MTX, TPRED, PRED20
159MCAnteriorIdiopathic69MTX,TPRED28
165MCIntermediateIdiopathic35MTX, TPRED20
175MCPosteriorIdiopathic3.55MTX, TPRED16
1811FHPosteriorIdiopathic811MTX, TPRED, PRED, AZA20
198FHPosteriorIdiopathic6.58MTX, TPRED, PRED12
2018FHPosteriorSarcoidosis1318MTX,TPRED50

MD2113MCPanuveitisIdiopathic913MTX, TPRED, PRED46
2215FHPanuveitisIdiopathic1315MTX, TPRED20
2314MCPanuveitisIdiopathic1214MTX, TPRED, PRED22
2415MCPanuveitisIdiopathic1315MTX, TPRED20
2516FHPanuveitisIdiopathic1316MTX, TPRED28
2611MCPanuveitisIdiopathic811MTX28
2716FHPanuveitisIdiopathic1416MTX/TPRED22
2814MCPanuveitisBlau syndrome914MTX, TPRED, PRED48

LD2912FHAnteriorPoly JIA10.512MTX, PRED, TPRED8
308FHAnteriorERA68MTX/CYS/TPRED22
3110FCAnteriorPoly JIA8.510MTX/TPRED8
3212MAAnteriorOligo JIA10.512MTX/TPRED6
3311MCAnteriorOligo JIA9.511MTX/TPRED8
3412FCAnteriorOligo JIA8.512MTX/TPRED12

HD-high dose; MD-moderate dose; LD-low dose; M-male; F-female; H-hispanic; C-caucasian; A-african american; ERA-enthesitis-related arthritis; Poly JIA-polyarticular juvenile idiopathic arthritis; oligo JIA-oligoarticular juvenile idiopathic arthritis; MTX-methotrexate; PRED-prednisone; AZA-azathioprine; TPRED-topical prednisone; CYS-cyclosporine; MMF-mycophenolate mofetil; PSA-psoriatic arthritis; VKH-vogt-koyanagi-harada syndrome; CNO-chronic noninfectious osteomyelitis; Yr-year; Mo-month.